Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Inv. presentation
Employment agrmnt
|
|
TITAN PHARMACEUTICALS INC (TTNP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
SC 13D
| Sire Group Ltd. reports a 16.7% stake in Titan Pharmaceuticals, Inc. |
| 10/04/2023 |
3
| Sire Group Ltd. (10% Owner) has filed a Form 3 on TITAN PHARMACEUTICALS INC |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/31/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/31/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 07/20/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/28/2023 |
4/A
| Lazar David E. (CEO) has filed a Form 4 on TITAN PHARMACEUTICALS INC|
Txns:
| Sold 3,388,902 shares
@ $1.23, valued at
$4.2M
Sold 359,066 shares
@ $1.23, valued at
$441.7k
|
|
| 06/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 05/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits Interactive ... |
| 01/26/2023 |
4
| Lazar David E. (CEO) has filed a Form 4 on TITAN PHARMACEUTICALS INC|
Txns:
| Bought 37,500 shares
@ $0.9659, valued at
$36.2k
Bought 20,000 shares
@ $1.0033, valued at
$20.1k
|
|
| 01/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/15/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/21/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/30/2022 |
3
| Ben-Tzvi Avraham (Director) has filed a Form 3 on TITAN PHARMACEUTICALS INC |
| 08/25/2022 |
3
| McMurdo Matthew Charles (Director) has filed a Form 3 on TITAN PHARMACEUTICALS INC |
|
|
|